AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deOCT 253 min read$GMAB

Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab (GMAB) reported updated Phase 2 trial results for petosemtamab in metastatic colorectal cancer, showing 75% and 67% objective response rates in first- and second-line settings, respectively. The data supports ongoing Phase 3 trials and was presented at ESMO Congress 2026. Petosemtamab is an investigational bispecific antibody targeting EGFR and LGR5.

Original reporting
finanznachrichten.de
Published Oct 25, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
9/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The Phase 2 results provide a tangible efficacy signal that could de‑risk the upcoming Phase 3 trials and affect the company's valuation.

02

Market read

First‑time disclosure of strong Phase 2 efficacy data; likely catalyst for Genmab and related oncology biotech stocks.

03

What to watch

Long‑term durability and comparative efficacy versus existing EGFR therapies remain uncertain.

Relevance 9/10Novelty 9/10Timing: post‑ESMO presentation today

Background

Genmab is a Copenhagen‑based biotech developing bispecific antibodies; petosemtamab targets EGFR and LGR5 in colorectal cancer.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab announced updated Phase 2 follow‑up data showing 75% objective response rate in first‑line metastatic colorectal cancer patients.

Expected impact

likely upward pressure as market prices in the strong response rates.

Evidence & confidence

The data are a first‑time disclosure of high efficacy, a material catalyst for a biotech with an upcoming Phase 3 program.

Market effects

Sector

Boosts sentiment for oncology biotech stocks and may raise valuations of similar bispecific antibody programs.

Regional

European markets could see a modest rally in biotech indices following the announcement.

Global

Adds positive momentum to the global biotech sector, potentially influencing investor appetite for late‑stage trial news.

Counterpoint

What could challenge this read

Skeptics may argue the sample size is limited and safety signals could temper enthusiasm.

Key entities

  • company
    Genmab A/S

    Biotech firm developing petosemtamab.

  • drug
    Petosemtamab (GEN1158)

    Investigational bispecific antibody targeting EGFR and LGR5.

Read at source← All news

StoryGenmab reports 75% and 67% objective response rates in Phase 2 colorectal cancer trial

Also covered by

1 outlet

Related articles

OCT 25
$GMABMedAI 8/10

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study o

Genmab (GMAB) reported updated Phase 2 trial data for petosemtamab, showing 75% and 67% objective response rates in 1L and 2L mCRC patients, respectively. The study, presented at ESMO 2026, supports ongoing Phase 3 trials. Petosemtamab, targeting EGFR and LGR5, is being evaluated in multiple solid tumors. Genmab will host an investor update on October 28.

gurufocus.com2 min
OCT 25
$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

investing.com2 min
OCT 25
$GMABMedAI 8/10

Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC

Genmab reported updated Phase 2 data for petosemtamab plus chemo in metastatic colorectal cancer, showing 75% ORR in 1L and 67% in 2L, with 81% in 1L left-sided tumors. Median follow-up was 5.9 and 7.1 months. Most responses were confirmed. This update supports Genmab’s shift into late-stage GI oncology.

tradingview.com2 min
OCT 24
$GMABMed

Genmab and Incyte agree to colorectal cancer trial

Genmab and Incyte will collaborate on a Phase 1/2 trial combining Genmab's petosemtamab with Incyte's INCB161734 and chemotherapy for first-line colorectal cancer with KRAS G12D mutation. Genmab will lead the study, with Incyte co-funding and supplying its drug. Both companies' shares closed at $43.79 and $115.71 respectively before the announcement.

mugglehead.com2 min